Hepatocyte Growth Factor (HGF) Concentration in Myocardial Infarction

NCT01233336 | Completed

• 1 other identifier: 2.52/VII/10
• Study Type: observational
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

This is the continuation of previous study (registration number: NCT00844987) which revealed that hepatocyte growth factor (HGF) is a very early, good marker of myocardial injury and prognostic factor for post myocardial infarction (MI) cardiovascular events presence in long-term follow-up. Due to potentially very important implication of the results of previous study it was decided to continue research of HGF in patients with MI. Now, is scheduled to examine 100 consecutive patients with STEMI. HGF assessments will be performed just after admission to hospital, 1h and 24h later and before discharge. Two follow-up visits were planned i.e. at 3 and 6 months after MI. During hospitalization and at 6 month visit the echocardiography examination will be performed. The composite primary endpoint consists of cardiovascular events observed during hospital course and in long term-follow-up.

Conditions

Acute Coronary Syndrome; Myocardial Infarction

Keywords

ACS,; HGF,; myocardial infarction; markers of myocardial injury; acute coronary syndrome (ACS); prognostic factors in patients with ACS

Outcome Measures

Primary Outcomes (1)

• composite end point

  death, reinfarction, coronary interventions (PCI and/or CABG) due to new ACS or exacerbation of angina, symptoms of heart failure, rehospitalisation due to cardiovascular events and stroke in context of HGF concentration in acute stage of ACS

  6-month follow -up

Secondary Outcomes (3)

• death

  6- month follow-up

• symptoms of heart failure

  6-month follow-up

• rehospitalisation due to cardiovascular reasons

  6- month follow-up

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with acute coronary syndrome admitted to CCU due to symptoms of ACS.

You may qualify if:

• age \>18 years,
• chest pain,
• symptoms of ischemia at ECG,
• signed informed consent form

You may not qualify if:

• age \< 18 years,
• not signed informed consent form.

Sponsors & Collaborators

• National Institute of Cardiology, Warsaw, Poland: lead

Study Sites (1)

Institute of Cardiology , CCU, ul. Alpejska 42

Warsaw, 04-628, Poland

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

plasma for HGF concentration

MeSH Terms

Conditions

Acute Coronary Syndrome; Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 2, 2010
• First Posted: November 3, 2010
• Study Start: July 1, 2010
• Primary Completion: December 1, 2012
• Study Completion: December 1, 2012
• Last Updated: February 5, 2013

Record last verified: 2013-02

Locations

PL (1)